for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inventiva SA

IVA.OQ

Latest Trade

13.81USD

Change

-0.34(-2.40%)

Volume

1,524

Today's Range

13.50

 - 

13.94

52 Week Range

10.52

 - 

19.14

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
14.15
Open
13.94
Volume
1,524
3M AVG Volume
0.81
Today's High
13.94
Today's Low
13.50
52 Week High
19.14
52 Week Low
10.52
Shares Out (MIL)
38.66
Market Cap (MIL)
478.22
Forward P/E
-9.55
Dividend (Yield %)
--

Next Event

Full Year 2021 Inventiva SA Earnings Release

Latest Developments

More

Inventiva Completes Sale Of $30 Million Through ATM Program

Inventiva Says FDA's Fast Track Designation To Lanifibranor In NASH Encompasses Treatment With Compensated Cirrhosis

Inventiva H1 Net Operating Loss Widens To 23.6 Million Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Inventiva SA

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Industry

Business Services

Contact Info

50 rue de Dijon, Daix

21121

France

+33.3.80447500

http://inventivapharma.com/

Executive Leadership

Frederic Cren

Chief Executive Officer, Co-Founder

Pierre Broqua

Co-Founder, Chief Scientific Officer

Jean Volatier

Chief Financial Officer

Nathalie Harroy

Head of Human Resources

Jerome Bernard

Vice President Business Development

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (EUR)

2018

-1.640

2019

-1.280

2020

-0.990

2021(E)

-1.226
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,366.34
Price To Book (MRQ)
5.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.40
LT Debt To Equity (MRQ)
11.39
Return on Investment (TTM)
-56.35
Return on Equity (TTM)
-44.21

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up